Jubilant Pharmova Limited

NSEI:JUBLPHARMA 주식 보고서

시가총액: ₹179.1b

Jubilant Pharmova 관리

관리 기준 확인 1/4

Jubilant Pharmova CEO는 Priyavrat Bhartia, Jun2023 에 임명되었습니다 의 임기는 1.42 년입니다. 총 연간 보상은 ₹ 67.47M, 37.1% 로 구성됩니다. 37.1% 급여 및 62.9% 보너스(회사 주식 및 옵션 포함). 는 ₹ 1.58B 가치에 해당하는 회사 주식의 0.88% 직접 소유합니다. 1.58B. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 6.8 년입니다.

주요 정보

Priyavrat Bhartia

최고 경영자

₹67.5m

총 보상

CEO 급여 비율37.1%
CEO 임기1.4yrs
CEO 소유권0.9%
경영진 평균 재임 기간1.8yrs
이사회 평균 재임 기간6.8yrs

최근 관리 업데이트

Recent updates

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Nov 15
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Oct 27
A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Aug 24
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Jul 13
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Mar 14
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth

Dec 23
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth

These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Dec 02
These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Jul 26
These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

May 11
Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Dec 10
Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00

Aug 01
Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00

Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?

Jun 15
Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?

Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Mar 22
Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Feb 15
Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Dec 20
Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year

Sep 15
Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year

Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly

Aug 21
Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly

Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook

Jun 08
Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook

An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued

May 25
An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued

Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts

Feb 10
Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts

Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)

Feb 08
Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)

CEO 보상 분석

Priyavrat Bhartia 의 보수는 Jubilant Pharmova 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

₹6b

Jun 30 2024n/an/a

₹6b

Mar 31 2024₹67m₹25m

₹771m

보상 대 시장: Priyavrat 의 총 보상 ($USD 798.47K )은 Indian 시장( $USD 502.40K ).

보상과 수익: Priyavrat 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.


CEO

Priyavrat Bhartia (48 yo)

1.4yrs

테뉴어

₹67,466,997

보상

Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...


리더십 팀

이름위치테뉴어보상소유권
Priyavrat Bhartia
MD & Director1.4yrs₹67.47m0.88%
₹ 1.6b
Arjun Bhartia
Joint MD & Director1.4yrs₹67.47m데이터 없음
Arvind Chokhany
Group CFO & Whole-Time Director1.5yrs₹44.78m데이터 없음
Prakash Bisht
Executive VP of Group Accountsno data데이터 없음데이터 없음
Laxshmivarahan Ramasubramani
Group Chief Digital & Information Officerno data₹16.53m데이터 없음
Surajit Pal
Head of Investor Relationsno data데이터 없음데이터 없음
Sanjay Gupta
Executive VP & Head of Legal10yrs₹3.34m데이터 없음
Naresh Kapoor
Company Secretary & Compliance Officer2.3yrs₹6.86m데이터 없음
Shantanu Jha
Group Chief Human Resources Officer1.8yrs데이터 없음데이터 없음
Rajagopal Sankaraiah
Advisor4.7yrs₹67.29m데이터 없음
A. Srivastava
Senior Vice President of Corporate Affairsno data데이터 없음데이터 없음
Chandan Sengar
President of Life Science Chemicalsno data₹19.34m데이터 없음

1.8yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: JUBLPHARMA 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Priyavrat Bhartia
MD & Director7.5yrs₹67.47m0.88%
₹ 1.6b
Arjun Bhartia
Joint MD & Director7.5yrs₹67.47m데이터 없음
Arvind Chokhany
Group CFO & Whole-Time Director3.6yrs₹44.78m데이터 없음
Arul Ramakrishan
Additional Director & Whole-time Directorless than a year데이터 없음데이터 없음
Shyam Sunder Bhartia
Chairman46.4yrs데이터 없음0.085%
₹ 151.8m
Sushil Roongta
Independent Non-Executive Director7.5yrs₹2.59m데이터 없음
Arun Seth
Independent Non-Executive Director6.1yrs₹2.01m0.0013%
₹ 2.3m
Harsh Mahajan
Independent Directorless than a year데이터 없음데이터 없음
Hari Bhartia
Co-Chairman41yrs₹124.06m0.23%
₹ 419.7m
Shivpriya Nanda
Independent Directorless than a year데이터 없음데이터 없음
Vivek Mehra
Independent Non-Executive Director7.5yrs₹2.53m데이터 없음
Shirish Belapure
Additional Independent Non-Executive Director1.7yrs₹2.23m데이터 없음

6.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: JUBLPHARMA 의 이사회경험(평균 재직 기간 6.8 년)으로 간주됩니다.